Serum M30 and M65 values in patients with advanced stage non-small-cell lung cancer compared with controls

USTAALIOGLU, Basak; BILICI, Ahmet; ERCAN, Serif; ORCUN, Asuman; SEKER, Mesut; OZKAN, Alper; USTAALIOGLU, Recep; Gumus, MAHMUT

doi:10.1007/s12094-012-0808-0

Serum M30 and M65 values in patients with advanced stage non-small-cell lung cancer compared with controls

Atıf İçin Kopyala

USTAALIOGLU B. O. , BILICI A., ERCAN S., ORCUN A., SEKER M., OZKAN A., ...Daha Fazla

CLINICAL & TRANSLATIONAL ONCOLOGY, cilt.14, sa.5, ss.356-361, 2012 (SCI İndekslerine Giren Dergi)

Cilt numarası: 14 Konu: 5
Basım Tarihi: 2012
Doi Numarası: 10.1007/s12094-012-0808-0
Dergi Adı: CLINICAL & TRANSLATIONAL ONCOLOGY
Sayfa Sayıları: ss.356-361

Özet

M30 and M65 are derivatives of cytokeratin 18 and released from the epithelial cell during cell death. These markers can be used to evaluate prognosis and chemotherapy response in several tumours. We evaluated serum M30 and M65 values in patients with advanced non-small-cell lung cancer (NSCLC) compared with those in a healthy group.